DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 3, 2016, reports the cash position of DBV Technologies S.A. as of September 30, 2016. DBV Technologies is a biopharmaceutical company developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases. The company has no approved products for sale as of the filing date.
Key Financial Metrics
| Metric | Value |
|---|---|
| Cash and Cash Equivalents (Sept 30, 2016) | €277.6 million |
| Cash and Cash Equivalents (Dec 31, 2015) | €323.4 million |
| Outstanding Shares (Sept 30, 2016) | 24,642,828 |
| Fully Diluted Shares (Sept 30, 2016) | 27,151,653 |
| Revenue, Profit, and Debt | Not provided in this filing |
Material Changes
Cash and cash equivalents decreased by €45.8 million, representing a decline from €323.4 million at the end of 2015 to €277.6 million as of September 30, 2016. The filing does not provide a detailed breakdown of operating expenses or specific cash burn rates for the period.
Outlook, Risks, and Management Commentary
DBV Technologies is advancing clinical trials for Viaskin Peanut and Viaskin Milk, with preclinical development ongoing for Viaskin Egg. The company is also exploring applications for Eosinophilic Esophagitis and vaccines. Management highlights substantial risks, including the uncertainty of clinical trial results, regulatory approvals, and the fact that no products are currently authorized for sale. The filing includes standard forward-looking statement disclaimers regarding these uncertainties.
Investor Verification Checklist
- Verify the specific operational expenses driving the €45.8 million reduction in cash reserves.
- Confirm the current status and enrollment numbers for the Viaskin Peanut and Viaskin Milk clinical trials.
- Review the company's most recent Form 20-F for comprehensive revenue, debt, and liquidity details not included in this 6-K.
- Assess the timeline for potential regulatory submissions based on the progress of ongoing clinical studies.